Which dogs and cats should be screened for heart disease?

Three groups: breed-at-risk animals (Cavaliers, Dachshunds, Chihuahuas for MMVD; Dobermans, Boxers, Great Danes for DCM; Maine Coons, Ragdolls, Bengals for HCM), any small-breed dog over about 8 years or middle-aged-to-senior cat, and any patient with a murmur, gallop, arrhythmia, or unexplained cough or exercise intolerance.

How often should at-risk pets be screened?

Annually for most at-risk breeds, and in Maine Coons and Ragdolls echocardiographic screening ideally starts at 1–2 years of age. A single normal NT-proBNP is a snapshot, not a clearance — the value of screening is the trend across repeated visits.

What is the difference between screening and diagnosis?

Screening is for patients with no signs — it uses cheap, fast tools (auscultation, NT-proBNP) to decide who needs a full workup. Diagnosis characterizes the disease and stages it, using echocardiography. Screening decides who gets diagnosed; diagnosis decides how they are treated.

How does NT-proBNP fit into screening?

It is the pivot: one blood draw with a 10–20 minute result that quantifies cardiac wall stress. A rising trend across annual screens — even inside the normal range — flags a progressor before signs appear. Cut-offs of ~265 pmol/L (cat) and ~1158 pmol/L (dog) separate cardiac from respiratory causes when signs are ambiguous.

Heart Disease Screening in Dogs and Cats: Who, When, Why

Q: What is a red flag at home?

A sleeping or resting cat breathing more than about 30–40 breaths per minute, or a dog that coughs at night or tires early on walks. Owners can count resting respiratory rate at home; a sustained rise is one of the earliest signs of impending heart failure and should trigger a visit, not a wait-and-see.

Q: Is screening a healthy pet worth it?

Yes, for the right patients. MMVD reaches 85% prevalence in small dogs by 13 and HCM ~15% in cats, yet both are silent until decompensation. Catching disease at B1 (median ~5-year survival) versus first presenting in heart failure is the difference between years and months of quality life.

TL;DR — Heart disease in dogs and cats is a numbers game: MMVD reaches 85% prevalence in small dogs by age 13 and HCM hits ~15% of cats, yet both are silent until the patient decompensates. Screening is how you catch them while there are still years of runway — a dog found at B1 lives a median ~5 years; a dog that first presents in heart failure does not. The protocol is simple: know your at-risk breeds, screen them annually, teach owners one home metric (a sleeping cat breathing >30–40 breaths/min is a red flag), and let a serial NT-proBNP trend — not a single value — decide who graduates to echocardiography.

In Plain Terms

Screening is not diagnosis. Diagnosis answers “what disease does this sick patient have?” Screening answers a quieter question: “which of these healthy-looking patients is quietly developing one?”

That distinction matters because most heart disease is caught too late — not because the tests are hard, but because nobody runs them on a patient who looks fine. This page is the checklist for who, when, and why.

Who to Screen: The Three Lists

List 1 — Breed at risk

Species	Disease	Breeds
Dog	MMVD	Cavalier King Charles Spaniel, Dachshund, Chihuahua, Poodle, small terriers
Dog	DCM	Doberman, Boxer, Great Dane, Irish Wolfhound
Cat	HCM	Maine Coon, Ragdoll, Bengal, Sphynx

List 2 — Age

Any small-breed dog over ~8 years (MMVD prevalence climbs steeply after this point).
Any middle-aged-to-senior cat (HCM is not strictly age-gated — it can appear in young adults).

List 3 — The ambiguous sign

A cough that “won’t clear” after two rounds of routine treatment.
Exercise intolerance that the owner writes off as “slowing down.”
A murmur, gallop rhythm, or arrhythmia found incidentally.
A sleeping/resting respiratory rate above 30–40 breaths/min in a cat.

The One Home Metric That Saves Cats

Owners cannot auscultate, but they can count breaths. A resting or sleeping cat that consistently breathes more than about 30–40 breaths per minute is a genuine early-warning sign of impending heart failure — often weeks before a crisis. This is the single highest-leverage thing to teach an owner of an at-risk cat, because it turns “wait until the cat looks sick” into “call us when the number climbs.”

For dogs, the equivalent signals are a nighttime cough and tiring earlier on walks — both of which owners routinely normalize as “old age.”

How Often: The Annual Principle

At-risk breeds: annual screening, and for Maine Coons and Ragdolls echocardiographic screening ideally starts at 1–2 years and repeats yearly.
Seniors: fold a screening NT-proBNP into the annual wellness panel for small dogs over ~8 and older cats.
Known disease: serial NT-proBNP at 3–6 month intervals to track progression.

The core principle: a single normal result is a snapshot, not a clearance. The entire diagnostic power of screening lives in the trend — a value that climbs across two or three annual screens is the signal that a patient is progressing, even if every individual value sits inside the “normal” range.

Why the Trend Beats the Single Value

This is the concept that separates good screening from box-ticking:

A stable, in-range NT-proBNP across two years → reassuring; the valve or muscle is not progressing meaningfully.
A value that climbs 20–30% year over year, even while technically “normal” → the patient is a progressor; escalate to echo.

The reason the trend is trustworthy where the single value is not: NT-proBNP has individual variation, but within one patient a rising series is a reproducible signal of increasing wall stress. It is the same logic as tracking creatinine in a CKD cat — the slope matters more than the absolute number.

Screening vs. Diagnosis: A Clean Division of Labor

	Screening	Diagnosis
Patient	No signs	Signs or suspicious screen
Tools	Auscultation, NT-proBNP	Echocardiography
Cost	Low	Higher, may need referral
Question	“Who needs a closer look?”	“What exactly is it, and what stage?”
Frequency	Annual	As indicated

Screening decides who gets diagnosed; diagnosis decides how they are treated. Mixing the two — sending every healthy Cavalier for an echo, or trying to screen with echo alone — is how practices either waste money or miss cases.

What Screening Is Worth to a Clinic

It fills the wellness visit with medicine. A senior wellness panel that includes NT-proBNP gives the vet something concrete to act on, instead of a “everything looks fine” handshake.
It creates a defensible record. When an at-risk breed is screened annually and the trend is documented, the clinic has a clear, objective basis for escalating care — and is protected if the disease later declares itself.
It catches the disease early, which is better for the patient and cheaper for the owner. A dog managed from B1 has years of good life; a dog that first presents in failure has already lost that runway.

A Ready-to-Use Screening Plan

Identify the at-risk animals on the books (breed + age lists above).
Screen annually: auscultation + NT-proBNP on a quantitative immunofluorescence analyzer (10–20 min).
Teach owners the home metric (resting respiratory rate for cats; cough/exercise tolerance for dogs).
Escalate any rising NT-proBNP trend or abnormal auscultation to echocardiography.
Monitor confirmed disease with serial NT-proBNP at 3–6 month intervals.

Related products: Canine NT-proBNP Test · Feline NT-proBNP Test · FIA680 Analyzer · FIA880 Analyzer

FAQ

Which dogs and cats should be screened?

3 lists — breed-at-risk (Cavaliers/Dachshunds/Chihuahuas for MMVD; Dobermans/Boxers/Great Danes for DCM; Maine Coons/Ragdolls/Bengals for HCM), any small dog over ~8 years or older cat, and any patient with a murmur, gallop, or unexplained cough.

How often?

Annually for at-risk breeds, with Maine Coon/Ragdoll echo starting at 1–2 years. A single normal NT-proBNP is a snapshot, not a clearance — the value is the trend.

What is a red flag at home?

A sleeping cat breathing >30–40 breaths/min, or a dog with a nighttime cough or early fatigue. A sustained rise in resting respiratory rate is one of the earliest signs of impending failure.

Screening vs diagnosis?

2 different questions — screening (no signs, cheap tools: auscultation + NT-proBNP) decides who needs a workup; diagnosis (echo) characterizes and stages. Screening decides who gets diagnosed.

Is screening a healthy pet worth it?

Yes — MMVD hits 85% of small dogs by 13 and HCM ~15% of cats, both silent until decompensation. Catching B1 (median ~5 years survival) versus first presenting in failure is years versus months of life.

How does NT-proBNP fit?

It is the pivot — one draw, 10–20 min, quantifies wall stress. A rising trend across annual screens flags a progressor before signs. Cut-offs: ~265 pmol/L (cat), ~1158 pmol/L (dog).

Key Takeaways

Screen the lists, not everyone — breed-at-risk, small dogs >8 years, and older cats. Blanket screening is waste; targeted screening is where the cases are.
Teach the home metric — a sleeping cat breathing >30–40 breaths/min is an early failure warning. This one instruction turns owners into an early-warning system.
The trend beats the value — a single normal NT-proBNP is a snapshot. A 20–30% year-over-year climb, even “in range,” is the real signal to escalate to echo.
Annual is the rhythm — at-risk breeds yearly; Maine Coons/Ragdolls echo from 1–2 years; confirmed disease every 3–6 months.
Early beats late every time — B1 dogs live a median ~5 years; first presentation in heart failure is a different, much shorter story. Screening is how you buy those years back.

References

Keene BW, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 2019. PMID 31389076
Payne JR, et al. Population characteristics and survival in cats with hypertrophic cardiomyopathy. J Vet Intern Med. 2010. PMID 20840126
Fox PR, et al. NT-proBNP in feline respiratory distress. J Vet Intern Med. 2011;25(5):1010–1016. PMID 21848947
Porciello F, et al. Resting respiratory rate as a home-monitoring tool in cardiac cats. J Vet Cardiol. (representative)
Boswood A, et al. NT-proBNP in canine cardiac vs respiratory disease.

This content is for educational and product-selection purposes only. It is not a substitute for veterinary diagnosis — any animal with suspected heart disease should be evaluated by a veterinarian. Reference ranges are platform-dependent; always use the intervals validated for your specific analyzer. Product specifications are as published by Migibio (Guangzhou Magic Biotech Co., Ltd.) and may change.